Rotterdam

• Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies Recruiting
  2022-501797-19-00 1 2023-07-13 Acute Myeloid Leukemia (AML)
• Continuing Somatostatin Analogues Upon progression in Neuroendocrine tumour pAtients (SAUNA trial) Recruiting
  2022-502703-30-00 6 2023-06-28 neuroendocrine tumours
• A Phase 1 Safety and Dose Finding Study of 131I -TLX101 Plus Standard of Care in Patients with Newly Diagnosed Glioblastoma Recruiting
  2024-515466-13-00 3 2023-06-28 Glioblastoma multiforme (GBM)
• The RiCOTTA study: Rifampicin Combination Therapy versus Targeted Antibiotic Monotherapy for Infected Joint Prostheses Caused by Staphylococ … Recruiting
  2022-501620-26-00 6 2023-05-15 prosthetic joint infection
• The ACTION Study: ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy Recruiting
  2022-502051-56-00 5 2023-04-28 H3 K27M-mutant diffuse glioma
• Peroperative Administration of Tranexamic acid in gastric bypass to reduce haemorrhage in patients with morbid obesity Recruiting
  2024-513570-22-00 5 2023-04-28 Morbid obesity
• Reduction of blood loss in pediatric surgical procedures around the hip - A trial with tranexamic acid Recruiting
  2024-516324-34-01 6 2023-04-17 Slipped capital femoral epiphysis (SCFE)
• A Phase 1 Study to Determine the Safety, and Pharmacokinetics of the Selective MET kinase Inhibitor, DO-2 in Patients With Advanced or Refra … Recruiting
  2023-504897-39-00 1 2023-04-13 Advanced or refractory solid tumours (Part 1)
• A Phase 2/3 Randomized, Placebo-Controlled, Double-blind, Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vericigua … Recruiting
  2022-501238-52-00 10 2023-03-23 Heart failure due to systemic left ventricular systolic dysfunction
• A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394, an inhibitor of BRAF Class 1 and Class 2 alterations, in participan … Recruiting
  2024-513578-23-00 4 2023-03-21 Tumors harboring BRAF alterations
• (SPARROW) Standard versus Pre-emptive Antibiotic Treatment to Reduce the Rate of Infectious Outcomes after Whipple’s procedure (SPARROW): a … Recruiting
  2024-510766-16-00 11 2023-03-06 Pancreatoduodenectomy with a high risk for contaminated bile
• Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis Subjects 1 Through 11 Years of Age Recruiting
  2024-513754-29-00 5 2023-03-06 Cystic Fibrosis
• A study of MP0533 in patients with blood cancer. Recruiting
  2023-505259-39-00 7 2023-03-02 Acute Myeloid Leukemia (AML)
• Long-term safety and tolerability of inclisiran in participants with heterozygous familial hypercholesterolaemia or homozygous familial hype … Recruiting
  2023-507278-41-00 5 2023-02-10 Familial hypercholsterolemia
• A Trial to Evaluate EP 104GI in Adults with Eosinophilic Esophagitis (EoE) (RESOLVE) Recruiting
  2024-516689-13-00 9 2023-02-06 Eosinophilic esophagitis
• A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants with Ulcerative Colitis or Crohn’s Disease (SHINE-ON) Recruiting
  2023-506239-14-00 5 2022-12-13 Crohn’s Disease
• A modular, first time in human, open label, multiple dose, accelerated escalation with cohort expansion study of the safety and pharmacokine … Recruiting
  2023-506818-45-00 7 2022-12-13 Solid tumors that have a high incidence of Homologous Recombination (H
• Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells Recruiting
  2023-507041-28-00 4 2022-11-28 Solid and Hematological Malignancies
• A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neu … Recruiting
  2024-510990-21-00 10 2022-11-11 Mucopolysaccharidosis Type II [MPS II]
• Renal Lifecycle Trial: A Randomized Controlled Clinical Trial to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in … Recruiting
  2023-508389-13-00 5 2022-11-08 Combined endpoint of all-cause mortality, kidney failure, and hospital
• Prevention of opioid-induced constipation in patients with advanced cancer. Recruiting
  2023-509462-38-00 11 2022-10-25 Patients with advanced cancer.
• HOVON 161: A phase II non-inferiority study comparing point-of-care produced CAR T-cell to commercial CAR T-cells in patients with relapsed/ … Recruiting
  2024-511979-15-00 4 2022-10-14 relapsed/refractory Non-Hodgkin Lymphoma
• Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone versus Lenalidomide Alone in Participants With Newly Dia … Recruiting
  2023-510384-36-00 5 2022-09-13 Newly Diagnosed Multiple Myeloma
• Pharmacokinetic-guided dosing of emicizumab in congenital haemophilia A patients – The DosEmi study Recruiting
  2024-515528-35-00 11 2022-09-08 Congenital Haemophilia A

Showing 385–408 of 818 trials